Surgery – Means for introducing or removing material from body for... – Infrared – visible light – ultraviolet – x-ray or electrical...
Patent
1997-06-11
1999-11-30
Coggins, Wynn Wood
Surgery
Means for introducing or removing material from body for...
Infrared, visible light, ultraviolet, x-ray or electrical...
607152, A61N 130
Patent
active
059958693
ABSTRACT:
A device and method are provided for reducing or preventing skin sensitization in electrotransport drug delivery. The method involves co-administration of a countersensitizing agent, comprising cis-urocanic acid or an analog thereof, with the drug delivered via electrotransport. Novel drug reservoirs and electrotransport drug delivery systems, formulated with a countersensitizing agent as described herein, are provided as well.
REFERENCES:
patent: 4885154 (1989-12-01), Cormier
patent: 4942883 (1990-07-01), Newman
patent: 5000956 (1991-03-01), Amkraut et al.
patent: 5049387 (1991-09-01), Amkraut
patent: 5077054 (1991-12-01), Amkraut et al.
patent: 5118509 (1992-06-01), Amkraut
patent: 5120545 (1992-06-01), Ledger et al.
patent: 5130139 (1992-07-01), Cormier et al.
patent: 5149539 (1992-09-01), Ledger et al.
patent: 5160741 (1992-11-01), Cormier
patent: 5171576 (1992-12-01), Amkraut et al.
patent: 5202130 (1993-04-01), Grant et al.
patent: 5304379 (1994-04-01), Cormier et al.
patent: 5451407 (1995-09-01), Cormier et al.
Rheins, et al., The Journal of Immunology, vol. 136, No. 3, pp. 867-876, Feb. 1, 1996, "Modulation of the Population Density of Identifiable Epidermal Langerhans Cells Assoicated with Enhancement or Suppression of Cutaneous Immune Reactivity."
Shimizu, et al., The Journal of Investigative Dermatology, vol. 101, No. 5, pp. 749-753 Nov. 1993, "Transepidermal Induction of Contact Hypersensitivity in Mice with a Water-Soluble Hapten."
Wille, J., et al,. Proceed. Intern. Symp. Control. Rel. Bioact. Mater., 22, pp. 119-120, No. 234 (1995), Controlled Release Society, Inc.,.
Drug Delivery Systems, Chapter 4, p. 155; Source: Reproduced from Behl C R et al., Iontophoretic Drug Delivery, Journal of Pharmaceutical Sciences, 78 (5), 355-360, 1989.
Reeve, Vivienne E., et al., Am. J Clin Nutr 1995; 61:571-576, "pyridoxine supplementation protects mice from suppression of contact hypersensitivity indeced by 2-acetyl-4-tetrahydroxybutylimidazole (THI), ultraviolet B radiation (280-320 nm), or cis-urocanic acid.sup.1-3 ".
Jaksic, et al., Photochemistry and Photobiology, vol. 61, No. 3, pp. 303-309, (1995), "Cis-Urocanic acid synergizes with histamine for increased PGE.sub.2 production by human keratinocytes: link to indomethacin-inhibitable UVB-induced immunosuppression".
Reeve, et al., Photochemistry and Photobiology, vol. 60, No. 3 pp. 268-273, 1994, "Lack of Correlation Between Suppression of Contact Hypersensitivity by UV Radiation and Photoisomerization of Epidermal Urocanic Acid in the Hairless Mouse".
Gilmour, et al., The Journal of Investigative Dermatology, vol. 101, No. 1, Aug., 1993, pp. 169-174, "Effect of Phototherapy and Urocanic Acid Isomers on Natural Killer Cell Function".
Guymer, et al., Transplantation, vol. 55, pp. 36-43, No. 1, Jan. 1993; "Urocanic Acid as an Immunosuppressant in Allotransplantation in Mice".
Hart, et al., The Journal of Immunology, vol. 150, pp. 4514-4523, No. 10, May 15, 1993, "Cis-Urocanic Acid Stimulates Human Peripheral Blood Monocyte Prostaglandin E.sub.2 Production and Suppresses Indirectly Tumor Necrosis Factor-.alpha. Levels".
Reeve, et al., "Hazards of Urocanic Acid as a Cosmetic Ingredient". Photodermatol Photoimmunol Photomed 1991: 8: pp. 176-180.
Gruner, et al., The Journal of Investigative Dermatology, vol. 98, No. 4, Apr. 1992, pp. 459-462, "Inhibition of Skin Allograft Rejection and Acute Graft- Versus-Host Disease by Cis-Urocanic Acid".
Kurimoto, et al., The Journal of investigative Dermatology, pp. 69S-70S, "Deleterious Effects of Cis-Urocanic Acid and UVB Radiation on Langerhans Cells and on Induction of Contact Hypersensitivity are Mediated by Tumor Necrosis Factor-Alpha".
Gilmour, et al., Photodermatology Photoimmunology & Photomedicine, 1992/1993; 9: pp. 255-261, "The Effect of Ultraviolet B irradtiation, cis-urocanic acid and tumour necrosis factor-.alpha. on delayed hypersensitivity to Herpes Simplex Virus".
Moodycliffe, et al., Immunology 1992 77 pp. 394-399, "The Effect of Ultraviolet B Irradiation and Urocanic Acid Isomer on Dendritic Cell Migration".
Gilmour, et al., Photodermatol Photoimmunol Photomed 1990; 7: pp. 243-248, "The Effect of Histamine Receptor Antagonists on Immunosuppression Induced by the Cis-Isomer of Urocanic Acid".
Norval, et al., Photochemistry and Photobiology, vol. 49, No. 5, pp. 633-639, 1989, "Urocanic Acid Analogues and the Suppression of the Delayed Type Hypersensitivity Response to Herpes Simplex Virus".
Norval, et al., Photochemistry and Photobiology, vol. 50, No. 2, pp. 267-275, 1989, "Urocanic Acid and Immunosuppression".
Ross, et al., Photodermatology 1988: 5: pp. 9-14, "Systemic Administration of Urocanic Acid Generates Suppression of the Delayed Type Hypersensitivity Response to Herpes Simplex Virus in a Murine Model of Infection".
Ross, et al., Viral Immunology, vol. 1, No. 3, pp. 191-198, 1987/1988, "Induction of Suppression of Delayed Type Hypersensitivity to Herpes Simplex virus by Epidermal Cells Exposed to UV-Irradiated Urocanic Acid In Vivo".
Shimizu, et al., Immunology 1994 82 pp. 140-148, "Evidence that Ultraviolet B Radiation Induces Tolerance and Impairs Induction of Contact Hypersensitivity by Different Mechanisms".
Bodde, et al., Critical Reviews in Therapeutic Drug Carrier Systems, vol. 6, Issue 1 (1989), pp. 87-115, "The Skin complaince of Transdermal Drug Delivery Systems".
Rasanen, et al., The Langerhans Cell. Ed., 1988, vol. 172, pp. 253-260, "Suppression of Human Epidermal Cell Secreted and Membrane Interleukin-1 Production by Cis-Urocanic Acid".
Mitra, et al., The Journal of Investigative Dermatology, Abstracts: No. 7, p. 490 Cis-Urocanic Acid and Histamine Augment TNF-.alpha. Medicated Induction of Keratinocyte ICAM-1-Expression and Supress IFN-.gamma. Induction of HLA-DR.
Shimizu, et al., TThe Journal of Investigative Dermatology, Abstracts: No. 458, p. 565, "UBV, TNF.alpha. and cis-Urocanic Acid Induce Tolerance to Hapten Via a Common, Non-TNF.alpha.-Dependent Mechanism".
Laurema, et al., The Journal of Investigative Dermatology, Abstract No. 644, p. 596, "Topical Cis-Urocanic Acid Suppresses Local Lymph Node Activation During Induction of Contact Hypersensitivity".
Roberts, et al., Clinical Research, vol. 38, No. 2, Apr. 1990, Cis-Urocanic Acid Induced Immunosuppression is Associated With A Prostaglandin-dependent Mechanism.
Fabo, et al., Photochem. Photobiol. 51 (Suppl) 1990, Abstract MPM-D12, "Cis-Urocanic Acid formulation by Ultraviolet B Irradiation of Skin Initiates UV Suppression of CHS in Mice".
Finlay-Jones, et al., Joint Meeting of the American Assoc. of Immun. and the Clinical Immunology society, Denver, CO, J. of Immunology 150 (8 part 2) 1993, "Cis-Urocanic Acid Stimulates Peripheral Blood Monocyte PGE.sub.2 Production and Suppresses Indirectly TNF.alpha. Levels".
Cormier Michel J. N.
Daddona Peter E.
Haak Ronald P.
Matriano James A.
ALZA Corporation
Bates Owen J.
Coggins Wynn Wood
Finkel Sharon
Miller D. Byron
LandOfFree
Reduction of skin sensitization in electrotransport drug deliver does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Reduction of skin sensitization in electrotransport drug deliver, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Reduction of skin sensitization in electrotransport drug deliver will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1686534